MSH2 and neoplasm: ARID1A alterations also compromise the mismatch repair interacting with MSH2 protein and ARID1A-deficient ovarian cancer cell line in syngeneic mice exhibited an increased number of tumor-infiltrating lymphocytes, a higher tumor mutation load and elevated PD-L1 levels [49].